EUVIMEDEUVIMED entdecken
Open Access

Familial Hypercholesterolemia Screening in Childhood and Early Adulthood

Brandon K Bellows, Yiyi Zhang, Natalia Ruiz-Negrón, Dhruv S Kazi, Amit V Khera, Jessica G Woo, Elaine M Urbina, David R Jacobs, Norrina B Allen, John B Wong, Sarah D de Ferranti, Andrew E Moran

JAMA · 13.01.2026 · 335 (2) · 140

DOI: 10.1001/jama.2025.20648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 13.01.2026. Verfasst von Brandon K Bellows und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Medicine, Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cholesterol, LDL, Cost-Effectiveness Analysis, Genetic Testing. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Heterozygous familial hypercholesterolemia (FH), a genetic condition, results in lifelong increased low-density lipoprotein cholesterol (LDL-C) and increases lifetime cardiovascular disease (CVD) risk. Most individuals with FH remain undiagnosed, so early FH identification and treatment could lower CVD burden.

Objective

To evaluate the projected cost-effectiveness of population sequential FH screening (lipid testing followed by genetic testing after a high LDL-C measurement) at 10 or 18 years of age. Design, Setting, and Participants The CVD Policy Model, a validated discrete event simulation of CVD risk factor management and CVD outcomes in National Health and Nutrition Examination Survey participants, was used to simulate lifetime health and economic outcomes from a health care sector perspective for a hypothetical cohort of 4.2 million US 10-year-olds. Individual characteristics and health care processes informed CVD events (coronary heart disease or stroke) and survival probabilities. Model inputs included national data sources, clinical trials, pooled longitudinal cohort studies, and published literature.

Interventions

Usual care assumed only opportunistic lipid testing and LDL-C and CVD risk-guided treatment. When added to usual care, sequential FH screening strategies examined combinations of childhood (age 10 years) or early adulthood (age 18 years) screening with 3 LDL-C thresholds (≥130 mg/dL, ≥160 mg/dL, or ≥190 mg/dL) to select patients for genetic testing. Main Outcomes and Measures Primary outcomes were direct health care costs (2021 US dollars), quality-adjusted life-years (QALYs), and an incremental cost-effectiveness ratio (ICER). Future costs and QALYs were discounted 3% annually. Strategies with an ICER of less than $100 000 per QALY gained were considered cost-effective.

Results

For the simulated cohort, usual care would lead to 3 118 000 (95% uncertainty interval, 3 061 000-3 192 000) total lifetime CVD events, with 16 182 (95% uncertainty interval, 15 683-16 827) among those with FH. Childhood FH screening could avert between 1385 and 1820 CVD events (<0.1% reduction in overall population), and early adulthood FH screening could avert between 1154 and 1448 CVD events (<0.1% reduction). While effective, no FH screening strategies were cost-effective relative to usual care; screening at age 18 years using an LDL-C threshold of 190 mg/dL or greater had the lowest ICER, at $289 700 per QALY gained. Sequential FH screening could become cost-effective vs usual care if lifetime lipid monitoring plus lifestyle therapy increased after a high screening LDL-C result, including for patients with non-FH dyslipidemias. Conclusions and Relevance Sequential FH screening in childhood or early adulthood could be effective but not cost-effective vs usual care. However, sequential FH screening could become cost-effective under highly optimistic assumptions about increased lifestyle therapy and increased lifetime lipid monitoring for patients with non-FH dyslipidemias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesCholesterol, LDLCost-Effectiveness AnalysisGenetic TestingHyperlipoproteinemia Type IIMass ScreeningAdolescentChildFemaleHumansMaleComputer SimulationCost of IllnessHealth Care CostsQuality-Adjusted Life Years

Substanzen

Cholesterol, LDL

Autor:innen und Institutionen

  • Division of General Medicine, Columbia University Irving Medical Center, New York, New York.
  • NDB Consulting Services LLC, St Cloud, Florida.
  • Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Verve Therapeutics, Boston, Massachusetts.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Bellows, B. K., Zhang, Y., Ruiz-Negrón, N., Kazi, D. S., Khera, A. V., Woo, J. G., Urbina, E. M., Jacobs, D. R., Allen, N. B., Wong, J. B., de Ferranti, S. D., & Moran, A. E. (2026). Familial Hypercholesterolemia Screening in Childhood and Early Adulthood. JAMA, 335(2), 140. https://doi.org/10.1001/jama.2025.20648

Vancouver

Bellows BK, Zhang Y, Ruiz-Negrón N, Kazi DS, Khera AV, Woo JG, et al. Familial Hypercholesterolemia Screening in Childhood and Early Adulthood. JAMA. 2026;335(2):140. doi:10.1001/jama.2025.20648

BibTeX
@article{Bellows2026,
  author = {Bellows, Brandon K and Zhang, Yiyi and Ruiz-Negrón, Natalia and Kazi, Dhruv S and Khera, Amit V and Woo, Jessica G and Urbina, Elaine M and Jacobs, David R and Allen, Norrina B and Wong, John B and de Ferranti, Sarah D and Moran, Andrew E},
  title = {Familial Hypercholesterolemia Screening in Childhood and Early Adulthood},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {2},
  pages = {140},
  doi = {10.1001/jama.2025.20648}
}
Kostenlos starten →